Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;107(2):324-332.
doi: 10.1002/cpt.1627. Epub 2019 Oct 11.

Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases

Joseph A DiMasi  1 , Maria I Florez  1 , Stella Stergiopoulos  1 , Yaritza Peña  1 , Zachary Smith  1 , Michael Wilkinson  1 , Kenneth A Getz  1
Affiliations

Development Times and Approval Success Rates for Drugs to Treat Infectious Diseases

Joseph A DiMasi et al. Clin Pharmacol Ther. 2020 Feb.

Abstract

We gathered data from three pipeline databases and other public sources on development stage and clinical trial metrics for 1,914 investigational drugs, biologics, and vaccines and 2,769 clinical trials intended to treat a wide variety of infectious diseases. We included new molecular entities (NMEs), new formulations, and new combinations. Clinical trial times decreased from 2000-2008 to 2009-2017, varied by disease class, and were longer for trials with more subjects or more sites. Clinical approval success rates were higher for this set of diseases than those in the published literature for drugs across all therapeutic categories. NMEs to treat HIV had a success rate (16.0%) that was similar to those for drugs in general, whereas NME success rates for influenza and pneumonia were much higher (48.1% and 50.5%, respectively).

PubMed Disclaimer

Comment in

References

    1. DiMasi, J.A., Grabowski, H.G. & Hansen, R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20-33 (2016).
    1. DiMasi, J.A., Grabowski, H.G. & Vernon, J. R&D costs and returns by therapeutic category. Drug Inf. J. 38, 211-223 (2004).
    1. Kaitin, K.I. & DiMasi, J.A. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89, 183-188 (2011).
    1. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272-277 (2010).
    1. Hay, M., Thomas, D.W., Craighead, J.L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).

Publication types

MeSH terms

LinkOut - more resources